Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-13, Stock:JNJ, The news for the past five days is as follows:
2018-07-06: NEWS1: What the Second Half of 2018 Has in Store for Investors.NEWS2: What the Second Half of 2018 Has in Store for Investors.NEWS3: Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far).NEWS4: Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far).NEWS5: Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far).NEWS6: What the Second Half of 2018 Has in Store for Investors.NEWS7: Trade of the Day: Novocure Ltd (NVCR).NEWS8: Trade of the Day: Novocure Ltd (NVCR).NEWS9: Kiplinger Dividend 15: CVS Interrupts Its String of Hikes.NEWS10: Kiplinger Dividend 15: CVS Interrupts Its String of Hikes.NEWS11: Biogen's Alzheimer Disease Candidate Succeeds in Phase II.NEWS12: Biogen's Alzheimer Disease Candidate Succeeds in Phase II.NEWS13: Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough.NEWS14: IWB, JPM, JNJ, BAC: Large Outflows Detected at ETF.NEWS15: IWB, JPM, JNJ, BAC: Large Outflows Detected at ETF.NEWS16: 3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July.NEWS17: 3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July.NEWS18: Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs.NEWS19: Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs.NEWS20: JNJ’s CAR T Cell Therapy and Erdafitinib: Growth Drivers.NEWS21: Biogen&apos;s Alzheimer Disease Candidate Succeeds in Phase II.NEWS22: 3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July.NEWS23: Trade of the Day: Novocure Ltd (NVCR).NEWS24: JNJ’s Oncology Business Witnessed 45% Growth in Q1 2018.NEWS25: Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks.NEWS26: Darzalex Could Boost JNJ’s Revenue Growth in 2018.
2018-07-09: NEWS1: JNJ Partners with Mercy for Real-World Data Insights for Research.NEWS2: Johnson & Johnson’s Medical Devices Business.NEWS3: Johnson & Johnson’s Erleada Approved by Health Canada.NEWS4: Johnson & Johnson Stock Only Benefits from Big Moves That May Not Come.NEWS5: The Performance of Johnson & Johnson’s Cardiovascular Segment.NEWS6: Why RBC Capital Markets Lowered Its Target Price on JNJ Stock.NEWS7: Johnson & Johnson’s Pulmonary Hypertension Business.
2018-07-10: NEWS1: Dow ETF in Focus Ahead of Q2 Earnings.NEWS2: Dow ETF in Focus Ahead of Q2 Earnings.NEWS3: See Which Of The Latest 13F Filers Holds Johnson & Johnson.NEWS4: See Which Of The Latest 13F Filers Holds Johnson & Johnson.NEWS5: JNJ’s Vision Care Segment Witnessed Solid Growth in Q1 2018.NEWS6: A Performance Overview of JNJ’s Surgical Medical Devices Business.NEWS7: How Is Johnson & Johnson’s Orthopedics Business Positioned?.
2018-07-11: NEWS1: Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2.NEWS2: Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2.NEWS3: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018.NEWS4: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018.NEWS5: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS6: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS7: Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares.NEWS8: Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline.
2018-07-12: NEWS1: Johnson & Johnson's Official Statement in Response to Today's Verdict in St. Louis Trial.NEWS2: Nearly $4.7 billion awarded in baby powder lawsuit.NEWS3: St. Louis Jury Returns $4.69 Billion Verdict in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer.NEWS4: Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case.NEWS5: The Latest: Jury awards nearly $4.7 billion in powder case.NEWS6: Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case.NEWS7: J&J Ordered to Pay $4.14 Billion Punitive Damages.NEWS8: $550 million awarded in lawsuit linking cancer, baby powder.NEWS9: Cramer: Most market-watchers are wrong. Stocks just aren't that expensive.NEWS10: REPLAY: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth.NEWS11: Jury orders J&J to pay $550 mln in Missouri asbestos cancer case.NEWS12: J&J Ordered To Pay $4.69 Bln In Baby Powder Case.NEWS13: J&J Ordered To Pay $4.69 Bln In Baby Powder Case.NEWS14: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS15: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS16: Markets Right Now: Tech gains push Nasdaq to all-time high.NEWS17: J&J Ordered to Pay $550 Million in Talc Asbestos Cancer Case.NEWS18: Drug Makers Can't Cure Investor Impatience.NEWS19: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS20: Bank Earnings: JPMorgan, Wells Fargo And Citigroup Are Slated To Report Friday Morning.NEWS21: Johnson & Johnson's Breakout May Boost Stock 11%.NEWS22: Two Dow stocks to buy and one to fade in a volatile market.NEWS23: Pfizer (PFE) to Reorganize Business Into Three New Units.NEWS24: Pfizer (PFE) to Reorganize Business Into Three New Units.NEWS25: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS26: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS27: Markets Right Now: Technology stocks lead US rebound.NEWS28: Video: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth.NEWS29: Why Jim Cramer Is Bullish on Johnson & Johnson Shares.NEWS30: Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings.NEWS31: What Analysts Think of Endo International.NEWS32: J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What&apos;s Up?.

Answer: Decrease